Voyager Therapeutics's quarterly market cap
declined
from Sep. 2025 (€211.61 Mil) to Dec. 2025 (€192.73 Mil) but then
increased
from Dec. 2025 (€192.73 Mil) to Mar. 2026 (€195.65 Mil).
Voyager Therapeutics's annual market cap
declined
from Dec. 2023 (€343.50 Mil) to Dec. 2024 (€308.68 Mil) and
declined
from Dec. 2024 (€308.68 Mil) to Dec. 2025 (€192.73 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Voyager Therapeutics's Enterprise Value for Today is €95.76 Mil.
Voyager Therapeutics (FRA:VT6) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Voyager Therapeutics Market Cap Related Terms
Voyager Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Voyager Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VT6 vs CRBU, OBIO, WHWK: Market Cap Comparison
For the Biotechnology subindustry, Voyager Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Voyager Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyager Therapeutics (FRA:VT6) has a Market Cap of €189.86 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Voyager Therapeutics and its competitors. According to the industry distribution chart, Voyager Therapeutics ranks #583 out of 1429 companies in the Biotechnology industry, placing it in the top 40.8%.
Is Voyager Therapeutics' Market Cap too high?
Voyager Therapeutics' current Market Cap is €189.86 Mil. Based on the distribution chart, Voyager Therapeutics ranks #583 out of 1429 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Voyager Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Market Cap compare to CRBU and OBIO?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #583 out of 1429 companies for Market Cap. This puts Voyager Therapeutics in the upper half of its industry. The industry median Market Cap is 112.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Voyager Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyager Therapeutics's current Market Cap is €189.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.39, compared to a current price of €2.94 — trading 111.8% above its estimated fair value. The current Market Cap is €189.86 Mil. Voyager Therapeutics' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Market Cap is €189.86 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of €2.94 is trading 111.8% above its estimated GF Value™ of €1.39.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:VT6:
Market Cap: €189.86 Mil
GF Value™: €1.39 vs. price of €2.94 (111.8% above fair value)
No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
57GF Score
Get the complete analysis for FRA:VT6
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VT6 has been successfully added to your 
